JP2023182736A5 - - Google Patents

Download PDF

Info

Publication number
JP2023182736A5
JP2023182736A5 JP2023173122A JP2023173122A JP2023182736A5 JP 2023182736 A5 JP2023182736 A5 JP 2023182736A5 JP 2023173122 A JP2023173122 A JP 2023173122A JP 2023173122 A JP2023173122 A JP 2023173122A JP 2023182736 A5 JP2023182736 A5 JP 2023182736A5
Authority
JP
Japan
Prior art keywords
inventions described
inventions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023173122A
Other languages
English (en)
Japanese (ja)
Other versions
JP7715778B2 (ja
JP2023182736A (ja
Filing date
Publication date
Priority claimed from PCT/JP2019/036239 external-priority patent/WO2020054871A1/ja
Application filed filed Critical
Publication of JP2023182736A publication Critical patent/JP2023182736A/ja
Publication of JP2023182736A5 publication Critical patent/JP2023182736A5/ja
Priority to JP2025119629A priority Critical patent/JP2025148537A/ja
Application granted granted Critical
Publication of JP7715778B2 publication Critical patent/JP7715778B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023173122A 2018-09-14 2023-10-04 ヒト抗il-33モノクローナル抗体含有医薬用組成物 Active JP7715778B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025119629A JP2025148537A (ja) 2018-09-14 2025-07-16 ヒト抗il-33モノクローナル抗体含有医薬用組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018173103 2018-09-14
JP2018173103 2018-09-14
PCT/JP2019/036239 WO2020054871A1 (ja) 2018-09-14 2019-09-13 ヒト抗il-33モノクローナル抗体含有医薬用組成物
JP2020546239A JP7407723B2 (ja) 2018-09-14 2019-09-13 ヒト抗il-33モノクローナル抗体含有医薬用組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020546239A Division JP7407723B2 (ja) 2018-09-14 2019-09-13 ヒト抗il-33モノクローナル抗体含有医薬用組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025119629A Division JP2025148537A (ja) 2018-09-14 2025-07-16 ヒト抗il-33モノクローナル抗体含有医薬用組成物

Publications (3)

Publication Number Publication Date
JP2023182736A JP2023182736A (ja) 2023-12-26
JP2023182736A5 true JP2023182736A5 (https=) 2024-03-12
JP7715778B2 JP7715778B2 (ja) 2025-07-30

Family

ID=69777862

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020546239A Active JP7407723B2 (ja) 2018-09-14 2019-09-13 ヒト抗il-33モノクローナル抗体含有医薬用組成物
JP2023173122A Active JP7715778B2 (ja) 2018-09-14 2023-10-04 ヒト抗il-33モノクローナル抗体含有医薬用組成物
JP2025119629A Pending JP2025148537A (ja) 2018-09-14 2025-07-16 ヒト抗il-33モノクローナル抗体含有医薬用組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020546239A Active JP7407723B2 (ja) 2018-09-14 2019-09-13 ヒト抗il-33モノクローナル抗体含有医薬用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025119629A Pending JP2025148537A (ja) 2018-09-14 2025-07-16 ヒト抗il-33モノクローナル抗体含有医薬用組成物

Country Status (5)

Country Link
US (1) US20220041709A1 (https=)
EP (1) EP3851121A4 (https=)
JP (3) JP7407723B2 (https=)
CN (3) CN120267817A (https=)
WO (1) WO2020054871A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3088517B1 (en) 2013-12-26 2023-11-01 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
IL272864B2 (en) 2017-08-31 2024-03-01 Mitsubishi Tanabe Pharma Corp Il-33 antagonist-containing therapeutic agent for endometriosis
JP7804590B2 (ja) * 2020-05-11 2026-01-22 メディミューン リミテッド 抗il-33抗体の処方物
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
CN113842457B (zh) * 2021-11-04 2022-05-20 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的液体制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US8821865B2 (en) * 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
CN107915769A (zh) * 2011-03-29 2018-04-17 葛兰素史密斯克莱有限责任公司 用于蛋白纯化的缓冲液体系
EP3088517B1 (en) * 2013-12-26 2023-11-01 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
WO2016031932A1 (ja) * 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるFc領域を有するタンパク質の製造方法
HRP20210096T1 (hr) * 2015-03-31 2021-03-05 Medimmune Limited Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe
JP6501650B2 (ja) * 2015-06-25 2019-04-17 田辺三菱製薬株式会社 ヒト抗il−33中和モノクローナル抗体
CN108718522A (zh) * 2016-02-23 2018-10-30 赛森生物股份有限公司 Il-6拮抗剂制剂及其用途
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
IL272864B2 (en) * 2017-08-31 2024-03-01 Mitsubishi Tanabe Pharma Corp Il-33 antagonist-containing therapeutic agent for endometriosis

Similar Documents

Publication Publication Date Title
JP2022068302A5 (https=)
JP2023116721A5 (https=)
JP2022028828A5 (https=)
JP2022025124A5 (https=)
JP2021185136A5 (https=)
JP2024059739A5 (https=)
JP2023022224A5 (https=)
JP2021038271A5 (https=)
JP2024016014A5 (https=)
JP2025506484A5 (https=)
JP2023100643A5 (https=)
JP2022060295A5 (https=)
JPWO2022202973A5 (https=)
JP2023182736A5 (https=)
JP2022537813A5 (https=)
JP2024112817A5 (https=)
JP2020171301A5 (https=)
JP2020120660A5 (https=)
JP2024534771A5 (https=)
JP2022544380A5 (https=)
JP2022022379A5 (https=)
JP2023011759A5 (https=)
JP2020141705A5 (https=)
JP2021129286A5 (https=)
JP2022122912A5 (https=)